Edgewise Therapeutics prices $200M common stock offering at $20.13 per share

Edgewise Therapeutics, Inc.

9,935,419 shares priced at $20.13; gross proceeds ~$200M before discounts and expenses.
Closing expected April 3, 2025; anticipated cash runway through 2028 (including existing cash).
Proceeds to fund sevasemten for Becker/Duchenne MD, EDG-7500 HCM trials, and R&D.
Participants include Braidwell, Cormorant, Driehaus, Invus, Janus, MPM, OrbiMed, Paradigm, Perceptive, RA Capital, Sofinnova.
Underwritten by Leerink, Piper Sandler, Guggenheim, and Truist Securities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.